Inspira Technologies has received US patent approval for its orbiting blood oxygenation delivery system (VORTX).

This system is a key component of the INSPIRA ART500 device, which is designed to enable breathing in patients who are awake, by measuring the real-time blood parameters of the patient continuously and delivering the necessary oxygen volume straight into the blood.

Inspira said the patented technology has 16 claims that have been recognised as novel.

The VORTX system is engineered to oxygenate blood while eliminating the use of fibre membranes.

Traditional fibre oxygenators force blood through layers of fibres, creating a turbulent flow that can lead to high hemolysis, damage to white blood cells, and activation of the body’s inflammatory and immune responses.

The VORTX system is capable of maintaining a more natural flow of blood, potentially reducing these harmful effects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Inspira expects the orbiting blood oxygenation delivery system to be a transformative technology for the INSPIRA ART500 device, which is targeting the $19bn mechanical ventilation market.

Inspira Technologies CEO Dagi Ben-Noon: “We believe that this is a monumental advancement in the landscape of blood oxygenation technologies and a pivotal milestone and another key indicator of the INSPIRA ART500’s core technological portfolio.”

To be equipped with Inspira’s HYLA blood sensor, the INSPIRA ART500 is being designed to scan the patient’s blood continuously.

In December 2023, Inspira reported that its HYLA blood sensor line (blood sensor) achieved 95% accuracy versus conventional blood gas analysers.

Said to be highly precise, not invasive, durable and a versatile tool for various procedures, the new sensor technology could provide continuous and real-time data collection and analysis of blood samples.